论文部分内容阅读
本实验对５０例卵巢粘液性囊腺癌中Ｃ－ｅｒｂＢ２（ｎｅｕ）癌基因，ｐ５３抗癌基因、ｐ２１蛋白（ｒａｓ基因产物）的表达进行研究，观察其在卵巢癌、交界性瘤、良性瘤的表达率，并采用半定量的ＡＢＣ免疫组化染色方法，研究不同强度表达与病理分化、临床分期、预后关系，得到初步结果。Ｃ－ｅｒｂＢ２在卵巢粘液癌中表达４８％，其限性表达率及表达强度与预后和病理分化有关。ｐ５３在卵巢粘液癌中表达４Ｏ％，但其表达率、表达强度与预后、手术分期和病理分化无明显相关性。ｐ２１在粘液癌中表达１２％，其表达率及强度与预后和病理分化无明显关系。在交界瘤、良性瘤中无表达。
The present study investigated the expression of C-erbB2 (neu) oncogene, p53 anti-oncogene, and p21 protein (ras gene product) in 50 cases of ovarian mucinous cystadenocarcinoma and observed it in ovarian cancer, borderline tumor, benign tumor The expression rate and the semi-quantitative ABC immunohistochemical staining method were used to study the relationship between different intensity expressions and pathological differentiation, clinical stage, and prognosis, and preliminary results were obtained. C-erbB2 is expressed in ovarian mucinous carcinoma by 48%. Its limiting expression rate and expression intensity are related to prognosis and pathological differentiation. Expression of p53 in ovarian mucinous carcinoma was 40%, but its expression rate, expression intensity and prognosis, surgical staging and pathological differentiation were not significantly correlated. P21 expression in mucinous carcinoma was 12%, and its expression rate and intensity were not significantly related to prognosis and pathological differentiation. No expression was found in borderline tumors or benign tumors.